Published online before print May 12, 2003, doi: 10.1161/01.CIR.0000074041.81728.79
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:2555.)
© 2003 American Heart Association, Inc.
Brief Rapid Communications |
Chymase Inhibition Prevents Cardiac Fibrosis and Improves Diastolic Dysfunction in the Progression of Heart Failure
From the Department of Cardiovascular and Respiratory Medicine (T.M., A.W., T.T., M.O., M.K.) and Central Research Laboratory (T.I.), Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Japan.
Correspondence to Atsuyuki Wada, MD, PhD, Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Japan. E-mail wada{at}belle.shiga-med.ac.jp
Background— Angiotensin (Ang) II, which plays a crucial role in the cardiac remodeling process, is generated via angiotensin-converting enzyme (ACE); however, an alternative generation pathway, chymase, which is stored in the mast cells, also exists in the heart. Cardiac chymase is insensitive to ACE inhibitors (ACEIs), and heart chymase promotes interstitial fibrosis by affecting collagen metabolism via transforming growth factor-ß in vitro. Therefore, selective chymase blockade seems to be an important strategy in the prevention of cardiac remodeling
Methods and Results— We evaluated the effects of a specific chymase inhibitor, SUNC8257 (Chy I; 10 mg/kg twice a day; n=7), on changes in cardiac structures, Ang II levels, and gene expressions, which are characterized as molecular markers for fibrosis, in dogs with tachycardia induced heart failure (HF). In HF, the number of chymase enzyme–positive mast cells increased in the left ventricle (LV) compared with the normal group; however, Chy I significantly decreased the mast cell density and cardiac Ang II levels. Despite no significant differences in LV systolic function compared with the vehicle group, Chy I decreased LV end-diastolic pressure and shortened the prolongation of 
. Chy I suppressed collagen-type I and III and transforming growth factor-ß mRNA levels and decreased fibrosis in the LV compared with the vehicle.
Conclusion— The chymase pathway may be critical for cardiac diastolic dysfunction accompanied with fibrosis. Chronic chymase inhibition may therefore become an important strategy in the prevention of cardiac remodeling in HF.
Key Words: angiotensin • diastole • fibrosis • heart failure
Related Article:
Circulation 2003 107: 2522-2524.
This article has been cited by other articles:
 |
|
 |
|
  H. Kanemitsu, S. Takai, H. Tsuneyoshi, E. Yoshikawa, T. Nishina, M. Miyazaki, T. Ikeda, and M. Komeda Chronic chymase inhibition preserves cardiac function after left ventricular repair in rats Eur. J. Cardiothorac. Surg., January 1, 2008; 33(1): 25 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Palaniyandi, Y. Nagai, K. Watanabe, M. Ma, P. T. Veeraveedu, P. Prakash, F. A. Kamal, Y. Abe, K. Yamaguchi, H. Tachikawa, et al. Chymase Inhibition Reduces the Progression to Heart Failure After Autoimmune Myocarditis in Rats Experimental Biology and Medicine, October 1, 2007; 232(9): 1213 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. W. Cheng, K. Obata, M. Kuzuya, H. Izawa, K. Nakamura, E. Asai, T. Nagasaka, M. Saka, T. Kimata, A. Noda, et al. Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure Hypertension, November 1, 2006; 48(5): 979 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-H. Fecteau, J.-C. Honore, M. Plante, J. Labonte, G. A. Rae, and P. D'Orleans-Juste Endothelin-1 (1-31) Is an Intermediate in the Production of Endothelin-1 After Big Endothelin-1 Administration In Vivo Hypertension, July 1, 2005; 46(1): 87 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Boerma, J. Wang, J. Wondergem, J. Joseph, X. Qiu, R. H. Kennedy, and M. Hauer-Jensen Influence of Mast Cells on Structural and Functional Manifestations of Radiation-Induced Heart Disease Cancer Res., April 15, 2005; 65(8): 3100 - 3107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Tchougounova, A. Lundequist, I. Fajardo, J.-O. Winberg, M. Abrink, and G. Pejler A Key Role for Mast Cell Chymase in the Activation of Pro-matrix Metalloprotease-9 and Pro-matrix Metalloprotease-2 J. Biol. Chem., March 11, 2005; 280(10): 9291 - 9296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. D. Xiao and K. E. Bernstein Mast Cells: The Missing Source of Cardiac Renin? Mol. Interv., February 1, 2005; 5(1): 11 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Kennedy, M. Hauer-Jensen, and J. Joseph Cardiac function in hearts isolated from a rat model deficient in mast cells Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H632 - H637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Heymans, F. Lupu, S. Terclavers, B. Vanwetswinkel, J.-M. Herbert, A. Baker, D. Collen, P. Carmeliet, and L. Moons Loss or Inhibition of uPA or MMP-9 Attenuates LV Remodeling and Dysfunction after Acute Pressure Overload in Mice Am. J. Pathol., January 1, 2005; 166(1): 15 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Funabiki, K. Onishi, K. Dohi, T. Koji, K. Imanaka-Yoshida, M. Ito, H. Wada, N. Isaka, T. Nobori, and T. Nakano Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2487 - H2492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Helske, K. A. Lindstedt, M. Laine, M. Mayranpaa, K. Werkkala, J. Lommi, H. Turto, M. Kupari, and P. T. Kovanen Induction of local angiotensin II-producing systems in stenotic aortic valves J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1859 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Kass, J. G.F. Bronzwaer, and W. J. Paulus What Mechanisms Underlie Diastolic Dysfunction in Heart Failure? Circ. Res., June 25, 2004; 94(12): 1533 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jin, S. Takai, M. Sakaguchi, Y. Okamoto, M. Muramatsu, and M. Miyazaki An Antiarrhythmic Effect of a Chymase Inhibitor after Myocardial Infarction J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 490 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Takeshita, M. Hayashi, S. Iino, T. Kondo, Y. Inden, M. Iwase, T. Kojima, M. Hirai, M. Ito, D. J. Loskutoff, et al. Increased Expression of Plasminogen Activator Inhibitor-1 in Cardiomyocytes Contributes to Cardiac Fibrosis after Myocardial Infarction Am. J. Pathol., February 1, 2004; 164(2): 449 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cardin, D. Li, N. Thorin-Trescases, T.-K. Leung, E. Thorin, and S. Nattel Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways Cardiovasc Res, November 1, 2003; 60(2): 315 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jin, S. Takai, M. Yamada, M. Sakaguchi, K. Kamoshita, K. Ishida, Y. Sukenaga, and M. Miyazaki Impact of chymase inhibitor on cardiac function and survival after myocardial infarction Cardiovasc Res, November 1, 2003; 60(2): 413 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. O. Kokkonen, K. A. Lindstedt, and P. T. Kovanen Role For Chymase in Heart Failure: Angiotensin II-Dependent or -Independent Mechanisms? Circulation, May 27, 2003; 107(20): 2522 - 2524. [Full Text] [PDF]
|
|